SGMO Trade on Jul 8, 2019 10:03 from Cklamb: Tradervue User Stock Trades.

SGMO-
Intraday Fundamentals-
• The first two patients treated at the 3e13 vg/kg dose level rapidly achieved normal, sustained Factor VIII (FVIII) levels with no reported bleeding events and no factor usage for as long as 24 weeks of follow-up
• The two patients more recently treated at the 3e13 vg/kg dose level demonstrated FVIII activity kinetics that appear consistent with the first two patients in this dose cohort at similar early time points
• SB-525 showed dose-dependent increases in FVIII activity levels across all dose cohorts evaluated
• FDA recently granted regenerative medicine advanced therapy (RMAT) designation for SB-525 gene therapy to treat severe hemophilia A
BRISBANE, Calif. & NEW YORK--(BUSINESS WIRE)-- Sangamo Therapeutics, Inc. (NASDAQ: SGMO), a genomic medicine company, and Pfizer, Inc. (NYSE: PFE) today announced updated results from the Phase 1/2 Alta study evaluating investigational SB-525 gene therapy for severe hemophilia A. The data showed that SB-525 was generally well-tolerated and demonstrated a dose-dependent increase in Factor VIII (FVIII) activity levels. The first two patients treated at the 3e13 vg/kg dose rapidly achieved normal levels of FVIII activity as measured using a chromogenic assay, with no reported bleeding events, and the response continues to be durable for as long as 24 weeks, the extent of follow-up. The two patients more recently treated at the 3e13 vg/kg dose level are demonstrating FVIII activity kinetics that appear consistent with the first two patients treated in
this dose cohort at similar early time points. Data from 10 patients treated with SB-525 were presented during an oral presentation on July 6 at the XXVII Congress of the International Society on Thrombosis and Haemostasis (ISTH), in Melbourne, Australia. The SB-525 ISTH presentation slides, which include the full data set, are available on Sangamo’s website in the Investors and Media section under Events and Presentations.
POSITIVE
Technicals

Trading strategy
Short if cannot hold 13 stop at 13.20 target 12.40
Long if it can hold 13.20 or on a retest of 13.20 stop at 13 target 13.80
Long over 13.80 with clean break for a trade to hold stop at 13.40

Reading the Tape

I had 12.40 as a level to pay attention to off the daily. I did see the momentum slow and rebound around the 12.30 level the again. It would not break 12.30 after the retrace to .25. I however did not see what exactly happened there.
Trade Management

• Tape held positive as it based above VWAP
• 10c off on the level that I had 12.30-12.25 was more likely the pivot
• Real risk was vwap at 12.61
• This was a great scalp 4 minute trade 2 to 1 off the first set stop 3to1 off vwap
•